Cocrystal pharma to present data from phase 1 study of first-in-class norovirus protease inhibitor cdi-988 at the 9th international calicivirus conference

Bothell, wash., july 10, 2025 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) announces that its first-in-class pan-viral protease inhibitor cdi-988 has been selected for an oral presentation at the 9th international calicivirus conference being held september 7-11, 2025 in banff, alberta, canada.
COCP Ratings Summary
COCP Quant Ranking